NSE: JSLL · BSE: 544476
JEENA SIKHO LIFECARE LTD
Operates a hub-and-spoke network of Ayurvedic hospitals and sells Ayurvedic medicines and OTC wellness products. The Healthcare Services segment, which runs inpatient, outpatient, daycare and virtual-OPD treatments across hospitals, contributed 47.8% of FY26 revenue (₹383.4 crore). The Ayurvedic Products and Medicines segment, which makes and sells items like the Entero and NutriRoz OTC lines plus new pain-relief patches, contributed 51.9% (₹415.7 crore). Distribution for OTC products is being scaled through an Entero partnership that gives access to 1.25 lakh of India's 9 lakh chemists. Diagnostics inside the hospitals are run through a partnership with Chandan, currently at 34 centres generating ₹3 lakh/day and scaling to 64. Expansion includes 2,700-2,800 beds under development toward a 7,000-10,000 bed target over 3-5 years, plus international operations in UAE, Kazakhstan and Nepal. Other operating expenses (26.5% of revenue) and employee costs (18.5%) are the largest disclosed cost lines; materials cost is reported at 0.0% of revenue. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Ayurvedic Products and Medicines (52%), Ayurvedic Healthcare Services (48%), Others (0%). Asset-light, capital-light expansion of an Ayurvedic hospital chain and OTC wellness products franchise.
Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 801 |
| EBITDA (ex other income) | 349 |
| margin % | 43.6 |
| Owners' profit | 222 |
| EPS, as reported (₹) | 17.84 |
| ROE % · ROCE % | 47.5 · 54.5 |
| Debt / equity (x) | 0.00 |
| Cash from operations | 254 |
| Capex | (34) |
Exhibit 2: Quarterly performance, last 5 quarters
| ₹ crore | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|
| Revenue | 174 | 190 | 222 | 216 | 224 |
| Profit before tax | 69 | 79 | 89 | 61 | 88 |
| Net profit | 51 | 59 | 67 | 45 | 66 |
| EPS (₹) | 4.13 | 4.73 | 5.36 | 3.63 | 5.30 |
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Ayurvedic products/ medicines | 118 | 27.0 |
| Ayurvedic healthcare services | 95 | 21.8 |
| Others | 2 | 0.5 |
| Ayurvedic products/medicines | 122 | 27.8 |
| Ayurvedic Healthcare Sevices | 100 | 22.8 |
| Total, before eliminations | 437 | 100.0 |
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| JEENA SIKHO LIFECARE LTD ◆ | 4,323 | 18.3 | 9.26 | 12.0 | 47.5 | 52.2 | — | 47.4 |
| KAYA LIMITED | 468 | — | — | — | 63.0 | (91.1) | (4.1) | (12.4) |
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 18.3 | 26.6 | 31 of 87 | 65% |
| P/B | 9.3 | 1.9 | 74 of 83 | 11% |
| ROCE | 52.2 | 5.4 | 4 of 101 | 97% |
| ROE | 47.5 | 5.6 | 2 of 83 | 99% |
| Debt / Equity | 0.0 | 0.1 | 17 of 82 | 79% |
| EBITDA margin | 47.4 | 23.4 | 14 of 85 | 85% |
| Revenue growth | 28.8 | 12.1 | 15 of 89 | 84% |
| Profit growth | 28.5 | 17.5 | 37 of 83 | 56% |
| Market cap | 4323 | 303 | 20 of 103 | 81% |
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 10 Oct 2026 · Allotment of 23,374 equity shares under ESOS 2024 | capital market events | low | — | — |
| 7 Oct 2026 · Compliance certificate under SEBI Regulation 74(5) for September 2026 quarter | compliance | minimal | — | — |
| 5 Oct 2026 · Jeena Sikho launches 8 new Ayurvedic and nutraceutical products | business updates | medium | — | — |
| 1 Oct 2026 · Jeena Sikho gets NABH accreditation for Raipur hospital | business updates | medium | — | — |
| 30 Sept 2026 · Jeena Sikho Lifecare AGM 2026 results: All 15 resolutions approved | board shareholder meetings | low | — | — |
| 30 Sept 2026 · Promoter Bhavna Grover buys 25000 shares via open market | ownership changes | medium | — | — |
| 29 Sept 2026 · Promoter Bhavna Grover buys 35,000 shares in open market | ownership changes | medium | — | — |
| 28 Sept 2026 · 9th AGM held; Rs 4.50 dividend declared; key director appointments approved | board shareholder meetings | low | — | — |
| 25 Sept 2026 · Jeena Sikho Lifecare: Trading Window Closed from Oct 1 Ahead of Q2 Results | compliance | minimal | — | — |
| 23 Sept 2026 · BSE approves listing of 6.5 lakh shares under Jeena Sikho ESOS 2024 | capital market events | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.